4 Stocks Improving Performance Of The Health Care Sector

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

One out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 1 points (0.0%) at 15,277 as of Thursday, May 16, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,398 issues advancing vs. 1,509 declining with 138 unchanged.

The Health Care sector currently sits down 0.72 versus the S&P 500, which is down 0.10. A company within the sector that increased today was UnitedHealth Group ( UNH), up 0.54. On the negative front, top decliners within the sector include Biomarin Pharmaceutical ( BMRN), down 6.00, Alexion Pharmaceuticals ( ALXN), down 4.57, Bristol-Myers Squibb Company ( BMY), down 3.51, Vertex Pharmaceuticals ( VRTX), down 3.07 and Gilead ( GILD), down 3.16.

TheStreet Ratings group would like to highlight 4 stocks pushing the sector higher today:

4. Aegerion Pharmaceuticals ( AEGR) is one of the companies pushing the Health Care sector higher today. As of noon trading, Aegerion Pharmaceuticals is up $9.19 (19.57) to $56.16 on heavy volume Thus far, 1.8 million shares of Aegerion Pharmaceuticals exchanged hands as compared to its average daily volume of 541,500 shares. The stock has ranged in price between $47.45-$57.34 after having opened the day at $47.45 as compared to the previous trading day's close of $46.97.

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of novel therapeutics to treat debilitating and fatal rare diseases in the United States. Aegerion Pharmaceuticals has a market cap of $1.4 billion and is part of the drugs industry. Shares are up 87.6% year to date as of the close of trading on Wednesday. Currently there are 11 analysts that rate Aegerion Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Aegerion Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and feeble growth in its earnings per share. Get the full Aegerion Pharmaceuticals Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

3. As of noon trading, Teva Pharmaceutical Industries ( TEVA) is up $0.32 (0.81) to $40.00 on average volume Thus far, 2.2 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 4.1 million shares. The stock has ranged in price between $39.50-$40.06 after having opened the day at $39.56 as compared to the previous trading day's close of $39.68.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $33.9 billion and is part of the drugs industry. The company has a P/E ratio of 17.7, equal to the S&P 500 P/E ratio of 17.7. Shares are up 7.0% year to date as of the close of trading on Wednesday. Currently there are 11 analysts that rate Teva Pharmaceutical Industries a buy, no analysts rate it a sell, and 15 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a hold. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and a generally disappointing performance in the stock itself. Get the full Teva Pharmaceutical Industries Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

2. As of noon trading, Actavis ( ACT) is up $1.58 (1.28) to $125.46 on heavy volume Thus far, 1.1 million shares of Actavis exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $123.92-$126.53 after having opened the day at $124.17 as compared to the previous trading day's close of $123.88.

Actavis, Inc., an integrated specialty pharmaceutical company, engages in developing, manufacturing, marketing, selling, and distributing generic, branded generic, brand, biosimilar, and over-the-counter pharmaceutical products worldwide. Actavis has a market cap of $15.5 billion and is part of the drugs industry. Shares are up 44.0% year to date as of the close of trading on Wednesday. Currently there are 13 analysts that rate Actavis a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Actavis as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Actavis Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

1. As of noon trading, Baxter International ( BAX) is up $0.51 (0.72) to $71.06 on heavy volume Thus far, 2.6 million shares of Baxter International exchanged hands as compared to its average daily volume of 3.4 million shares. The stock has ranged in price between $70.36-$71.20 after having opened the day at $70.56 as compared to the previous trading day's close of $70.55.

Baxter International Inc., through its subsidiaries, develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. Baxter International has a market cap of $38.2 billion and is part of the health services industry. The company has a P/E ratio of 17.0, below the S&P 500 P/E ratio of 17.7. Shares are up 5.8% year to date as of the close of trading on Wednesday. Currently there are 13 analysts that rate Baxter International a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Baxter International as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Baxter International Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.
null

If you liked this article you might like

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

7 Stocks Under $10 Making Big Up Moves

7 Stocks Under $10 Making Big Up Moves

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

Wall Street Loses Gains After Fed's Unsurprising June Call

Wall Street Loses Gains After Fed's Unsurprising June Call

Stocks Turn Lower After Yellen Expresses Confidence in U.S. Economy

Stocks Turn Lower After Yellen Expresses Confidence in U.S. Economy